These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 29514003)

  • 1. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
    Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa Biofilms.
    Du J; Bandara HM; Du P; Huang H; Hoang K; Nguyen D; Mogarala SV; Smyth HD
    Mol Pharm; 2015 May; 12(5):1544-53. PubMed ID: 25793309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
    Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
    [No Abstract]   [Full Text] [Related]  

  • 4. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J; Klinger-Strobel M; Arnold K; Thamm J; Hartung A; Pletz MW; Makarewicz O; Fischer D
    Eur J Pharm Biopharm; 2018 Oct; 131():120-129. PubMed ID: 30063969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted treatment for biofilm-based infections using PEGylated tobramycin.
    Ding L; Wang G; Wang J; Peng Y; Cai S; Khan SU; Cui Z; Zhang X; Wu C; Smyth H
    J Control Release; 2024 Aug; 372():43-58. PubMed ID: 38866243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
    Rojo-Molinero E; Macià MD; Rubio R; Moyà B; Cabot G; López-Causapé C; Pérez JL; Cantón R; Oliver A
    Antimicrob Agents Chemother; 2016 May; 60(5):2912-22. PubMed ID: 26926631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 8. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobramycin Liquid Crystal Nanoparticles Eradicate Cystic Fibrosis-Related Pseudomonas aeruginosa Biofilms.
    Thorn CR; Carvalho-Wodarz CS; Horstmann JC; Lehr CM; Prestidge CA; Thomas N
    Small; 2021 Jun; 17(24):e2100531. PubMed ID: 33978317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
    Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
    Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin.
    Müller L; Murgia X; Siebenbürger L; Börger C; Schwarzkopf K; Sewald K; Häussler S; Braun A; Lehr CM; Hittinger M; Wronski S
    J Antimicrob Chemother; 2018 Oct; 73(10):2762-2769. PubMed ID: 29982453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
    Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
    J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF; Ferrati S; Moraga-Espinoza DF; Smyth HDC
    J Pharm Sci; 2018 Aug; 107(8):2172-2178. PubMed ID: 29698726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms.
    Ye T; Sun S; Sugianto TD; Tang P; Parumasivam T; Chang YK; Astudillo A; Wang S; Chan HK
    Int J Pharm; 2018 Dec; 552(1-2):130-138. PubMed ID: 30267753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual tobramycin and docosahexaenoic acid loaded nanoemulsions combating Pseudomonas aeruginosa-induced pulmonary infection.
    Sun Y; Lu T; Pan J; He H; Xu M; Chen Y; Chen Y; Fang P; Ye X; Li S; Hu H; Yu S
    Colloids Surf B Biointerfaces; 2024 Oct; 242():114088. PubMed ID: 39003845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms.
    Armijo LM; Wawrzyniec SJ; Kopciuch M; Brandt YI; Rivera AC; Withers NJ; Cook NC; Huber DL; Monson TC; Smyth HDC; Osiński M
    J Nanobiotechnology; 2020 Feb; 18(1):35. PubMed ID: 32070354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.